Skip to main content

Table 2 Subgroup analysis showing disease-specific risk with VDR TaqI polymorphism

From: Association of vitamin D receptor TaqI and ApaI genetic polymorphisms with nephrolithiasis and end stage renal disease: a meta-analysis

Model

Type of disease

N

OR

95% CI

P value

Allele contrast (A vs. a)

Overall

16

1.11

[1.0262; 1.1967]

0.009

 

ESRD

2

1.17

[1.0171; 1.3357]

0.028

 

NL

11

1.09

[0.9673; 1.2356]

0.153

 

DN

3

1.07

[0.9250; 1.2322]

0.371

Recessive model (AA vs. Aa+aa)

Overall

16

1.19

[0.9266; 1.5392]

0.170

 

ESRD

2

1.14

[0.8497; 1.5235]

0.386

 

NL

11

1.32

[0.8084; 2.1503]

0.268

 

DN

3

1.11

[0.8527; 1.4432]

0.439

Dominant model (AA+Aa vs. aa)

Overall

16

1.14

[1.0234; 1.2709]

0.017

 

ESRD

2

1.24

[1.0367; 1.4863]

0.019

 

NL

11

1.09

[0.9148; 1.2930]

0.342

 

DN

3

1.09

[0.8737; 1.3505]

0.456

Overdominant (Aa vs. AA + aa)

Overall

16

0.99

[0.8106; 1.2040]

0.904

 

ESRD

2

1.19

[0.9904; 1.4233]

0.063

 

NL

11

0.92

[0.6575; 1.2975]

0.647

 

DN

3

1.01

[0.8261; 1.2289]

0.940

pairw1 (AA vs. aa)

Overall

16

1.20

[1.0117; 1.4232]

0.036

 

ESRD

2

1.26

[0.9280; 1.7151]

0.138

 

NL

11

1.23

[0.9346; 1.6077]

0.141

 

DN

3

1.11

[0.8081; 1.5149]

0.528

pairw2 (AA vs. Aa)

Overall

16

1.16

[0.8525; 1.5857]

0.341

 

ESRD

2

1.01

[0.7443; 1.3803]

0.932

 

NL

11

1.30

[0.7200; 2.3483]

0.384

 

DN

3

1.09

[0.8304; 1.4407]

0.524

pairw3 (Aa vs. aa)

Overall

16

1.09

[0.9167; 1.2888]

0.337

 

ESRD

2

1.24

[1.0233; 1.4966]

0.028

 

NL

11

1.04

[0.7873; 1.3666]

0.795

 

DN

3

1.07

[0.8487; 1.3425]

0.577

Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us